DK1869171T3 - Virusrensning under anvendelse af ultrafiltrering - Google Patents

Virusrensning under anvendelse af ultrafiltrering

Info

Publication number
DK1869171T3
DK1869171T3 DK06724513T DK06724513T DK1869171T3 DK 1869171 T3 DK1869171 T3 DK 1869171T3 DK 06724513 T DK06724513 T DK 06724513T DK 06724513 T DK06724513 T DK 06724513T DK 1869171 T3 DK1869171 T3 DK 1869171T3
Authority
DK
Denmark
Prior art keywords
ultrafiltration
virus
virus cleaning
adenovirus
cleaning
Prior art date
Application number
DK06724513T
Other languages
English (en)
Other versions
DK1869171T4 (da
Inventor
Miranda Weggeman
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36572264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1869171(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of DK1869171T3 publication Critical patent/DK1869171T3/da
Publication of DK1869171T4 publication Critical patent/DK1869171T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
DK06724513.4T 2005-04-11 2006-04-11 Virusrensning under anvendelse af ultrafiltrering DK1869171T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67006405P 2005-04-11 2005-04-11
EP05102842 2005-04-11
PCT/EP2006/003722 WO2006108707A1 (en) 2005-04-11 2006-04-11 Virus purification using ultrafiltration

Publications (2)

Publication Number Publication Date
DK1869171T3 true DK1869171T3 (da) 2009-02-16
DK1869171T4 DK1869171T4 (da) 2016-01-18

Family

ID=36572264

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06724513.4T DK1869171T4 (da) 2005-04-11 2006-04-11 Virusrensning under anvendelse af ultrafiltrering

Country Status (10)

Country Link
US (1) US8574595B2 (da)
EP (1) EP1869171B2 (da)
CN (1) CN101155915B (da)
AT (1) ATE412737T1 (da)
AU (1) AU2006233800B2 (da)
CA (1) CA2602944C (da)
DE (1) DE602006003420D1 (da)
DK (1) DK1869171T4 (da)
ES (1) ES2317517T5 (da)
WO (1) WO2006108707A1 (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005305347A1 (en) * 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
US20080131955A1 (en) * 2006-11-30 2008-06-05 Canon U.S. Life Sciences, Inc. Method of Separating Target DNA from Mixed DNA
EP2195418B1 (en) * 2007-10-02 2012-12-12 PTC Phage Technology Center GmbH Process and system for the industrial scale purification of bacteriophages intended for bacteriophage therapy
KR101915445B1 (ko) * 2007-12-28 2018-11-05 박스알타 인코퍼레이티드 단백질의 역압 여과
US10273502B2 (en) * 2008-06-18 2019-04-30 Oxford Biomedica (Uk) Limited Virus purification
CA2742474C (en) 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
FR2944292B1 (fr) 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
AU2010305768B2 (en) 2009-10-15 2015-05-14 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
MX2012004222A (es) 2009-10-15 2012-06-08 Crucell Holland Bv Metodo para purificacion de particulas de adenovirus.
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
PL2575872T3 (pl) * 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
US8778653B2 (en) 2010-08-12 2014-07-15 Yisheng Biopharma Holdings Ltd. Method for reducing DNA impurities in viral compositions
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
CN103582700B (zh) 2011-03-25 2016-08-17 弗·哈夫曼一拉罗切有限公司 新的蛋白质纯化方法
DK2739293T3 (da) * 2011-08-05 2020-08-24 Sillajen Biotherapeutics Inc Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
CN102688485A (zh) * 2011-09-16 2012-09-26 扬州优邦生物制药有限公司 一种猪细小病毒灭活疫苗的制备方法
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
WO2013106337A1 (en) * 2012-01-09 2013-07-18 Sanofi Pasteur Biologics, Llc Purification of flaviviruses
AU2013231423B2 (en) 2012-03-12 2018-10-04 Janssen Vaccines & Prevention B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
CN103923883A (zh) * 2013-01-16 2014-07-16 辽宁成大生物股份有限公司 一种流感病毒的浓缩、纯化方法
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
WO2014202570A1 (en) 2013-06-17 2014-12-24 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
CA2920191C (en) 2013-07-18 2022-03-01 Children's Hospital Medical Center Methods of improving titer in transfection-based production systems using eukaryotic cells
CN103601793A (zh) * 2013-10-23 2014-02-26 乾元浩生物股份有限公司 一种禽用疫苗抗原纯化的方法
EP4218991A1 (en) * 2014-05-13 2023-08-02 Amgen Inc. Process control systems and methods for use with filters and filtration processes
JP6791848B2 (ja) 2014-05-21 2020-11-25 アンチェインド ラブス 緩衝液の交換のためのシステム及び方法
EP3172317B1 (en) * 2014-07-24 2019-05-01 Janssen Vaccines & Prevention B.V. Process for the purification of poliovirus from cell cultures
CN107466324B (zh) 2015-04-14 2022-01-14 扬森疫苗与预防公司 具有双向启动子的表达两种转基因的重组腺病毒
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
KR102638978B1 (ko) 2015-07-07 2024-02-22 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
CA3018139A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
KR102506895B1 (ko) 2016-04-05 2023-03-08 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
US11473105B2 (en) 2016-05-12 2022-10-18 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
KR102421049B1 (ko) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
EP3559216A1 (en) * 2016-12-22 2019-10-30 Blue Sky Vaccines GmbH Method for purifying virus
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
MX2019013659A (es) * 2017-05-15 2020-01-13 C-Lecta Gmbh Productos enzimaticos.
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CN107603959A (zh) * 2017-08-30 2018-01-19 四川大学 提高缓冲液盐离子浓度纯化病毒的方法
KR20200053518A (ko) 2017-09-15 2020-05-18 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 면역의 안전한 유도를 위한 방법
GB201806736D0 (en) * 2018-04-25 2018-06-06 Ge Healthcare Bioprocess R&D Ab Method for virus purification
CN111454914A (zh) * 2019-01-18 2020-07-28 嘉兴安宇生物科技有限公司 一种腺病毒快速纯化方法
US20220090140A1 (en) * 2019-05-14 2022-03-24 Janssen Biotech, Inc. Efficient Impurity Removal Using A Diafiltration Process
CN110129287B (zh) * 2019-05-15 2023-07-14 青岛蔚蓝生物制品有限公司 一种猪伪狂犬病毒双重超滤系统及纯化方法
CN111394390A (zh) * 2020-03-26 2020-07-10 赛诺（深圳）生物医药研究有限公司 用于新型冠状病毒基因疫苗的批量生产重组腺病毒的方法
CN111575244B (zh) * 2020-05-06 2021-07-23 江苏金迪克生物技术股份有限公司 一种低Vero细胞残留DNA狂犬病疫苗原液的制备方法
CN112226418B (zh) * 2020-09-25 2022-07-08 阜外华中心血管病医院 重组腺相关病毒纯化方法
CN116583598A (zh) * 2020-12-10 2023-08-11 阿斯利康(英国)有限公司 纯化腺病毒的方法
CN112899242A (zh) * 2021-02-03 2021-06-04 苏州博腾生物制药有限公司 慢病毒纯化工艺
CN113373120B (zh) * 2021-06-18 2022-04-26 浙江康佰裕生物科技有限公司 Gmp级逆转录病毒载体的纯化方法与应用
CN113817689B (zh) * 2021-11-22 2023-10-03 北京艺妙神州医药科技有限公司 慢病毒纯化工艺
CN115747017B (zh) * 2022-10-25 2023-06-09 上海华新生物高技术有限公司 一种腺病毒纯化装置

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434914B (sv) * 1975-07-07 1984-08-27 Jonsson U R S Forfarande for att ur en suspension av bakterier och ett vetskeformigt medium genom filtrering avskilja mediet under samtidig anrikning av bakterierna
US4435289A (en) * 1981-12-23 1984-03-06 Romicon, Inc. Series ultrafiltration with pressurized permeate
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US4808315A (en) 1986-04-28 1989-02-28 Asahi Kasei Kogyo Kabushiki Kaisha Porous hollow fiber membrane and a method for the removal of a virus by using the same
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2716682B1 (fr) 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
WO1997008298A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
AU3447097A (en) 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
ATE550429T1 (de) 1996-11-20 2012-04-15 Crucell Holland Bv Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6168944B1 (en) 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
DE69835813T2 (de) * 1997-01-31 2007-09-13 Schering Corp. Verfahren zur kultivierung von zellen und zur vermehrung von viren
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5947689A (en) 1997-05-07 1999-09-07 Scilog, Inc. Automated, quantitative, system for filtration of liquids having a pump controller
CN1142271C (zh) 1997-08-28 2004-03-17 第一制糖株式会社 适应非洲绿猴肾细胞的减毒的日本脑炎病毒和其疫苗
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
CA2320419C (en) 1998-02-17 2011-02-08 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
EE200000605A (et) 1998-04-22 2002-04-15 Genvec, Inc. Adenoviiruse efektiivne puhastamine
US5994134A (en) 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6342384B1 (en) 1998-08-21 2002-01-29 The University Of Va Patent Foundation Production of adenoviral vectors using serum-free suspension cell culture in a hollow fiber system
EP1977764A1 (en) 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
CA2356373A1 (fr) 1998-12-31 2000-07-13 Aventis Pharma S.A. Methode de separation de particules virales
US6120820A (en) * 1999-02-22 2000-09-19 Land O'lakes, Inc. Method of modifying the color of a dairy material
WO2000050573A1 (fr) 1999-02-22 2000-08-31 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
DE60045138D1 (de) 1999-05-17 2010-12-02 Crucell Holland Bv Rekombinantes Adenovirus des Ad26-Serotyps
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
US6168941B1 (en) 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
DE10022258A1 (de) 2000-05-08 2001-11-15 Bayer Ag Reinigung von Proteineinschlusskörpern durch Querstrom-Mikrofiltration
JP2004508064A (ja) 2000-09-15 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン
US6365395B1 (en) 2000-11-03 2002-04-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
IL152420A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
ATE496120T1 (de) 2001-03-01 2011-02-15 Bayer Schering Pharma Ag Konzentration und lyse von adenovirus-infizierten zellen in derselben prozesseinheit
CA2776391C (en) 2001-10-01 2015-03-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
AU2003220531B2 (en) 2002-03-29 2007-11-01 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
AU2003271738C1 (en) 2002-04-25 2008-04-17 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
PT1506287E (pt) 2002-05-14 2007-07-17 Merck & Co Inc Métodos de purificação de adenovírus
US20050095705A1 (en) 2003-04-15 2005-05-05 Michael Kadan Method for production of oncolytic adenoviruses
EP1633321A4 (en) 2003-06-18 2006-11-02 Onyx Pharma Inc METHOD FOR CLEANING VIRUS
EP1718738A2 (en) 2004-02-23 2006-11-08 Crucell Holland B.V. Virus purification methods

Also Published As

Publication number Publication date
AU2006233800A1 (en) 2006-10-19
EP1869171B2 (en) 2015-10-14
US8574595B2 (en) 2013-11-05
WO2006108707A1 (en) 2006-10-19
ES2317517T5 (es) 2016-01-21
CA2602944C (en) 2015-08-11
EP1869171B1 (en) 2008-10-29
CA2602944A1 (en) 2006-10-19
EP1869171A1 (en) 2007-12-26
ATE412737T1 (de) 2008-11-15
AU2006233800B2 (en) 2011-07-07
ES2317517T3 (es) 2009-04-16
DE602006003420D1 (de) 2008-12-11
CN101155915A (zh) 2008-04-02
US20090123989A1 (en) 2009-05-14
DK1869171T4 (da) 2016-01-18
CN101155915B (zh) 2013-12-04

Similar Documents

Publication Publication Date Title
DK1869171T3 (da) Virusrensning under anvendelse af ultrafiltrering
NO20071158L (no) Membraner for separasjoner som krever hoy selektivitet
EP3603777A4 (en) POROUS MEMBRANE FOR MEMBRANE DISTILLATION AND METHOD FOR OPERATING A MEMBRANE DISTILLATION MODULE
EP2808393A3 (en) Fucosylation-deficient cells
EA201290251A1 (ru) Системы и способы осмотического разделения
DK1940918T3 (da) Dimercaptanterminerede polythioetherpolymerer og fremgangsmåder til at fremstille og anvende samme
DK2280999T3 (da) Fremgangsmåde til fremstilling af mælkefraktioner, som er rige på sekretoriske immunglobuliner
EP1747059A4 (en) COMPOSITE MEMBRANES OF PERVAPORATION
DK2092064T3 (da) Fremgangsmåde til forberedende RNA-oprensning ved hjælp af HPLC
WO2010056639A3 (en) Unequal multipath protection of different frames within a superframe using different cyclic prefix lengths
DK1764025T3 (da) Sammenklappelig aftörringsplade
EA200701097A1 (ru) Рекомбинантные векторы вируса гриппа с тандемными транскрипционными единицами
BRPI0919083A2 (pt) processo para preparação de uma membrana, e, membrana assimétrica.
DK1713801T3 (da) Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
SE0500469L (sv) Distanselement för permeat
EP2365869A4 (en) MICROPOROUS MEMBRANE AND METHOD OF MANUFACTURING THE SAME
BR112015006223A2 (pt) unidade de tratamento de água subaquática e método para limpar a dita unidade
DK1904522T4 (da) Fremgangsmåde til rensning af g-csf
FI20050452A0 (fi) Virtauskone, sen liukurengastiiviste, liukurengastiivisteen runkokappale ja menetelmä liukurengastiivisteen kiinnittämiseksi virtauskoneeseen
DK1737820T3 (da) Asymmetrisk hydrogeneringsfremgangsmåde, som er nyttig til fremstilling af cycloalkanoindolderivater
MY197183A (en) High flux, cross-linked, fumed silica reinforced polyorganosiloxane membranes for separations
NZ596671A (en) Assays for influenza virus hemagglutinins
MX2010003053A (es) Proceso para fraccionar una mezcla de poliisocianatos.
BRPI0813823B8 (pt) métodos para concentração de uma solução de imunoglobulina por filtração de fluxo tangencial, e para produção de uma imunoglobulina
DK2212289T3 (da) Fremgangsmåde til fremstilling af 2,2-difluorethylamin-derivater ved hjælp af amid-hydrering